Sponsor content
358 result(s) found, displaying 91 to 100
-
Australian Public Assessment Report (AusPAR)Vaxneuvance, a vaccine, has been approved for the prevention of pneumococcal disease caused by Streptococcus pneumoniae.
-
Australian Public Assessment Report (AusPAR)AusPAR for Gardasil 9 (HPV 9-valent vaccine, recombinant) for prevention of anal cancer, precancerous or dysplastic lesions, external genital lesions, and infection caused by HPV in males.
-
Australian Public Assessment Report (AusPAR)Keytruda (pembrolizumab) for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in-situ (CIS) with or without papillary tumours who are ineligible for or have elected not to undergo cystectomy.
-
Cancellation by sponsorRequested by Merck Sharp & Dohme (Australia) Pty Ltd
-
Cancellation by sponsorRequested by Merck Sharp & Dohme (Australia) Pty Ltd
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for LAGEVRIO molnupiravir 200 mg capsules bottle.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for VAXNEUVANCE Pneumococcal 15-valent Conjugate Vaccine [CRM197 Protein], adsorbed 0.5 mL Suspension for intramuscular injection, Pre-filled syringe.
-
Australian Public Assessment Report (AusPAR)AusPAR for Keytruda (pembrolizumab) for the treatment of Oesophageal Cancer
-
Australian Public Assessment Report (AusPAR)AusPAR for Keytruda (pembrolizumab) for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in-situ (CIS) with or without papillary tumours who are ineligible for or have elected not to undergo cystectomy.
-
Australian Public Assessment Report (AusPAR)AusPAR for Keytruda (pembrolizumab) for the treatment relapsed or refractory classical Hodgkin Lymphoma